In this interview, Nigel Stapleton from Mabion shares the exciting news about their new “Unlocking the Future of Therapeutics” competition. It’s a great opportunity for innovators working on biologics, especially in cancer treatment. Mabion is offering €500,000 in development services to help develop and scale up the most promising projects — whether that’s a brand new therapy or a biosimilar that can make life-saving treatments more accessible. Nigel also talks about how they’re working with top cancer researchers to pick out the best candidates, all part of their mission to push forward the future of cancer care.
TWENTYFOURSEVENBIOPHARMA